25 May 2013
Keywords: onyx/bayer, nexavar, gains, ec, orphan, status, german
Article | 24 April 2006
German drugmaker Bayer and USA-based Onyx Pharmaceuticals says their co-developed anticancer agent Nexavar (sorafenib) has been granted
Orphan Drug status ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 April 2006
1 May 2006
24 May 2013
© 2013 thepharmaletter.com